EUVIMEDEUVIMED entdecken
Crossref

Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues

Adrianna N Tilton, Sasha Ottey, William Patterson, Ricardo Azziz iD

The Journal of Clinical Endocrinology & Metabolism · 18.11.2026 · 111 (12) · 3363-3366

DOI: 10.1210/clinem/dgag272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.07.2026. Verfasst von Adrianna N Tilton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Foundation for Research and Education Excellence, PCOS Challenge, National Polycystic Ovary Syndrome Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycystic ovary syndrome (PCOS), renamed polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder affecting 4% to 20% of women worldwide. Prior analysis (2006-2015) demonstrated that PCOS/PMOS received disproportionately less US National Institutes of Health (NIH) funding compared with other chronic disorders of similar prevalence and/or morbidity, namely rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE). A number of bipartisan advocacy efforts have been made since.

Objective

To determine the impact of current advocacy efforts on NIH funding for PCOS/PMOS research.

Methods

NIH Research Portfolio Online Reporting Tools were queried.

Results

In 2016-22, mean annual NIH funding for PCOS/PMOS was $31.8 M vs $262.4 M (RA), $66.1 M (TB), and $420.4 M (SLE), a 48%, 577%, −15% and 689% difference, respectively, compared to 2006-2015. In 2016-2022 PCOS/PMOS research received 533 awards from 16 NIH Institute/Centers (ICs), with 44.8% of funding arising from the National Institute of Child Health and Human Development, compared with 68.4% in the prior study period. RA, TB, and SLE funding came from 27, 36, and 27 ICs, respectively.

Conclusion

In 2016-2022, PCOS/PMOS research funding by the NIH increased by ∼50% compared to 2006-2015, albeit still less than the increase and total funding for RA and SLE. There appeared to be greater interest in PCOS/PMOS by a higher number of ICs. Recent advocacy efforts appear to be associated with increasing NIH funding. However, much remains to be done to address persistent disparities in research funding for this highly prevalent and morbid women's health disorder.

Schlagwörter

Stichwörter der Autor:innen

PCOSU.S. National Institutes of Healthpolycystic ovary syndromepolyendocrine metabolic ovarian syndromeresearch fundingwomen’s health

Autor:innen und Institutionen

  • Dept. of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • PCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA, USA.
  • Dept. of Healthcare Organization & Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Dept of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

ORCID-Profile: Ricardo Azziz

Förderung

  • Foundation for Research and Education Excellence
  • PCOS Challenge
  • National Polycystic Ovary Syndrome Association

Zitieren

APA

Tilton, A. N., Ottey, S., Patterson, W., & Azziz, R. (2026). Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues. The Journal of Clinical Endocrinology & Metabolism, 111(12), 3363-3366. https://doi.org/10.1210/clinem/dgag272

Vancouver

Tilton AN, Ottey S, Patterson W, Azziz R. Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues. The Journal of Clinical Endocrinology & Metabolism. 2026;111(12):3363-3366. doi:10.1210/clinem/dgag272

BibTeX
@article{Tilton2026,
  author = {Tilton, Adrianna N and Ottey, Sasha and Patterson, William and Azziz, Ricardo},
  title = {Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {12},
  pages = {3363--3366},
  doi = {10.1210/clinem/dgag272}
}
Kostenlos starten →